سعر باتروناج 50 مجم فيال للحقن الوريد 2024

Tigecycline 50 mg powder for intravenous infusion, single vial (glycylcycline/tetracycline-class antibacterial).

• Complicated skin and skin structure infections.Population: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)
• Complicated intra-abdominal infections.Population: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)
• Community-acquired bacterial pneumonia.Population: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)

• Most common (>5%): nausea, vomiting, diarrhoea, abdominal pain, headache and increased SGPT.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to tigecycline or any excipient; anaphylactic reactions have occurred.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased all-cause mortality versus comparators in a meta-analysis (risk difference 0.6%); reserve for situations when alternative treatments are not suitable.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not indicated for diabetic foot infection or hospital-acquired/ventilator-associated pneumonia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Pancreatitis (including fatal), hypofibrinogenaemia, tooth discoloration and enamel hypoplasia and inhibition of bone growth with use during tooth development or pregnancy have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• WarfarinMonitor prothrombin time or another suitable anticoagulation test.DailyMed (U.S. National Library of Medicine)
• Calcineurin inhibitors (tacrolimus, ciclosporin)Trough concentrations may increase; monitor serum levels to avoid toxicity.DailyMed (U.S. National Library of Medicine)

• Like other tetracyclines, may cause permanent tooth discoloration and reversible inhibition of bone growth when used in the second and third trimesters; no human data on birth defects or miscarriage; animal studies showed reduced fetal weight and delayed ossification.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; tetracyclines pass into breast milk, but low oral bioavailability means low expected infant exposure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.